aspirin has been researched along with Aortic Valve Stenosis in 65 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Aortic Valve Stenosis: A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been hypothesized that the ingestion of aspirin by women during pregnancy increases their infants' risk of certain congenital heart defects." | 7.67 | The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. ( Mitchell, AA; Shapiro, S; Werler, MM, 1989) |
| "The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI." | 5.30 | Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial. ( Bastos Fernandez, G; Baz Alonso, JA; Calvo Iglesias, F; Cequier Fillat, A; Cruz Gonzalez, I; De Miguel Castro, A; Fernandez Barbeira, S; Iñiguez Romo, A; Jimenez Diaz, VA; Juan Salvadores, P; Molina Navarro, E; Moreno, R; Ocampo Miguez, J; Ortiz Saez, A; Paredes Galan, E; Raposeiras Roubin, S; Romaguera, R; Serra Peñaranda, A; Tello-Montoliu, A; Valdes Chavarri, M, 2019) |
| "Several trials demonstrated that aspirin monotherapy compared with aspirin plus clopidogrel is associated with a lower incidence of bleeding without an increased risk of ischemic events in patients after transcatheter aortic valve replacement (TAVR); however, there remains a paucity of data to prove the necessity of even aspirin monotherapy." | 4.31 | No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry. ( Fukuda, K; Hayashida, K; Inohara, T; Kobari, Y; Mizutani, K; Naganuma, T; Shimizu, H; Shirai, S; Tabata, M; Tada, N; Takagi, K; Tsuruta, H; Ueno, H; Watanabe, Y; Yamamoto, M; Yamanaka, F; Yamawaki, M; Yashima, F, 2023) |
| " Additionally, he had undergone an aortic root dilatation and aortic valve replacement at the age of 10 because of progression of aortic and supra-aortic stenosis and had received chronic anticoagulation and antiplatelet therapy with warfarin and aspirin, respectively." | 4.02 | Spontaneous Spinal Epidural Hematoma in an Adult Patient with Complex Congenital Heart Disease. ( Ifuku, T; Nishiguchi, T, 2021) |
| "It has been hypothesized that the ingestion of aspirin by women during pregnancy increases their infants' risk of certain congenital heart defects." | 3.67 | The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. ( Mitchell, AA; Shapiro, S; Werler, MM, 1989) |
| "Prostacyclin (PGI2) release by human aortic tissue obtained at surgery was assessed in patients (n = 23) with ischaemic heart disease undergoing coronary artery bypass grafting (group 1) patients (n = 14) undergoing surgery for aortic stenosis (group 2), patients (n = 4) undergoing surgery for aortic regurgitation (group 3), and patients (n = 8) with ischaemic heart disease taking aspirin (group 4)." | 3.67 | Release of prostacyclin from the human aorta. ( Dandona, P; Jeremy, JY; Mikhailidis, DP; Tsang, V; Walesby, RK; Wright, JC, 1988) |
| "In a prospective study, the efficacy of a dipyridamole-aspirin regimen in prevention of thromboembolism was evaluated in 50 patients having isolated aortic valve replacement with the Model 2320 Starr-Edwards prosthesis." | 3.66 | Dipyridamole-aspirin as thromboembolic prophylaxis in patients with aortic valve prosthesis. Prospective study with the Model 2320 Starr-Edwards prosthesis. ( Bowen, TE; Brott, WH; Davia, J; Green, DC; Zajtchuk, R, 1981) |
| "Stroke and bleeding are complications after transcatheter aortic valve replacement (TAVR)." | 3.30 | Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis. ( Brouwer, J; Nijenhuis, VJ; Ten Berg, JM; van Bergeijk, KH; van den Heuvel, AFM; van der Werf, HW; van Ginkel, DJ; Voors, AA; Wykrzykowska, JJ, 2023) |
| "Treatment with aspirin alone after TAVI had greater safety benefits and was associated with similar valve function as DAPT." | 2.84 | Clinical Outcomes and Bioprosthetic Valve Function After Transcatheter Aortic Valve Implantation Under Dual Antiplatelet Therapy vs. Aspirin Alone. ( Ichibori, Y; Kuratani, T; Maeda, K; Mizote, I; Nakatani, S; Ohtani, T; Onishi, T; Sakata, Y; Sawa, Y; Torikai, K; Yamaguchi, O, 2017) |
| "Non-aspirin NSAID use was not associated with either AVC or CAC in either cohort." | 1.39 | Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. ( Budoff, M; Delaney, JA; Dragano, N; Elmariah, S; Erbel, R; Jöckel, KH; Kälsch, H; Kronmal, RA; Lehmann, N; Mahabadi, AA; Moebus, S; Möhlenkamp, S; Nasir, K; O'Brien, KD; Psaty, BM; Winterstein, AG, 2013) |
| "The case is presented of a hemophilia carrier, also affected by von Willebrand's disease, who underwent aortic valve replacement." | 1.25 | Open-heart surgery in von Willebrand's disease. ( Aris, A; Gale, H; Hussey, CV; Lepley, D; Pisciotta, AV, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (9.23) | 18.7374 |
| 1990's | 5 (7.69) | 18.2507 |
| 2000's | 5 (7.69) | 29.6817 |
| 2010's | 30 (46.15) | 24.3611 |
| 2020's | 19 (29.23) | 2.80 |
| Authors | Studies |
|---|---|
| Kobari, Y | 2 |
| Inohara, T | 3 |
| Tsuruta, H | 2 |
| Yashima, F | 3 |
| Shimizu, H | 2 |
| Fukuda, K | 3 |
| Naganuma, T | 2 |
| Mizutani, K | 3 |
| Yamawaki, M | 3 |
| Tada, N | 3 |
| Yamanaka, F | 3 |
| Shirai, S | 3 |
| Tabata, M | 3 |
| Ueno, H | 3 |
| Takagi, K | 2 |
| Watanabe, Y | 3 |
| Yamamoto, M | 3 |
| Hayashida, K | 4 |
| van Bergeijk, KH | 1 |
| van Ginkel, DJ | 1 |
| Brouwer, J | 2 |
| Nijenhuis, VJ | 3 |
| van der Werf, HW | 1 |
| van den Heuvel, AFM | 1 |
| Voors, AA | 1 |
| Wykrzykowska, JJ | 1 |
| Ten Berg, JM | 3 |
| Merdler, I | 1 |
| Rogers, T | 3 |
| Case, BC | 2 |
| Bhogal, S | 1 |
| Reddy, PK | 1 |
| Ben-Dor, I | 3 |
| Zhang, C | 2 |
| Satler, LF | 3 |
| Weissman, G | 2 |
| Waksman, R | 3 |
| Otsuka, T | 1 |
| Ohno, Y | 1 |
| Suzuyama, H | 1 |
| Asami, M | 1 |
| Izumo, M | 1 |
| Yamasaki, K | 1 |
| Nishina, H | 1 |
| Fuku, Y | 1 |
| Gryaznov, AA | 1 |
| Saeyeldin, A | 1 |
| Abdelbaky, M | 1 |
| Zafar, MA | 1 |
| Tanweer, M | 1 |
| Papanikolaou, D | 1 |
| Imran, M | 1 |
| Li, Y | 1 |
| Ziganshin, BA | 1 |
| Elefteriades, JA | 1 |
| Eckstein, J | 1 |
| Liu, S | 1 |
| Toleva, O | 1 |
| Yanagawa, B | 1 |
| Verma, S | 1 |
| Cheema, AN | 1 |
| Eikelboom, R | 1 |
| Belley-Côté, EP | 1 |
| Whitlock, RP | 1 |
| Anwar, S | 1 |
| Spence, E | 1 |
| Zawadka, M | 1 |
| Fahrni, G | 1 |
| Jeger, R | 1 |
| Mueller, C | 1 |
| Shults, C | 1 |
| Torguson, R | 1 |
| Shea, C | 1 |
| Parikh, P | 1 |
| Bilfinger, T | 1 |
| Cocke, T | 1 |
| Brizzio, ME | 1 |
| Levitt, R | 1 |
| Hahn, C | 1 |
| Hanna, N | 1 |
| Comas, G | 1 |
| Mahoney, P | 1 |
| Newton, J | 1 |
| Buchbinder, M | 1 |
| Moreno, R | 3 |
| Craig, P | 1 |
| Asch, FM | 1 |
| Garcia-Garcia, HM | 1 |
| Ullah, W | 1 |
| Zghouzi, M | 1 |
| Ahmad, B | 1 |
| Biswas, S | 1 |
| Zaher, N | 1 |
| Sattar, Y | 1 |
| Pacha, HM | 1 |
| Goldsweig, AM | 1 |
| Velagapudi, P | 1 |
| Fichman, DL | 1 |
| Prasad, A | 1 |
| Alraies, MC | 1 |
| Yerasi, C | 1 |
| Forrestal, BJ | 1 |
| Mintz, GS | 1 |
| Rodés-Cabau, J | 2 |
| Stabile, E | 2 |
| Barbanti, M | 3 |
| Costa, G | 1 |
| Mahmoodi, BK | 1 |
| Saito, T | 1 |
| Yoshijima, N | 1 |
| Tanaka, M | 1 |
| Trejo-Velasco, B | 1 |
| Tello-Montoliu, A | 2 |
| Cruz-González, I | 1 |
| Baz-Alonso, JA | 1 |
| Salvadores, PJ | 1 |
| Romaguera, R | 2 |
| Molina-Navarro, E | 1 |
| Paredes-Galán, E | 1 |
| Fernández-Barbeira, S | 1 |
| Ortiz-Saez, A | 1 |
| Bastos-Fernandez, G | 1 |
| De Miguel-Castro, A | 1 |
| Figueiras-Guzman, A | 1 |
| Iñiguez-Romo, A | 1 |
| Jimenez-Diaz, VA | 1 |
| Mach, M | 1 |
| Watzal, V | 1 |
| Cuhaj, C | 1 |
| Hasan, W | 1 |
| Poschner, T | 1 |
| Szalkiewicz, P | 1 |
| Strouhal, A | 1 |
| Adlbrecht, C | 1 |
| Delle-Karth, G | 1 |
| Grabenwöger, M | 1 |
| Winkler, B | 1 |
| Ifuku, T | 1 |
| Nishiguchi, T | 1 |
| Vavuranakis, MA | 1 |
| Kalantzis, C | 1 |
| Voudris, V | 1 |
| Kosmas, E | 1 |
| Kalogeras, K | 1 |
| Katsianos, E | 1 |
| Oikonomou, E | 1 |
| Siasos, G | 1 |
| Aznaouridis, K | 1 |
| Toutouzas, K | 1 |
| Stasinopoulou, M | 1 |
| Tountopoulou, A | 1 |
| Bei, E | 1 |
| Moldovan, CM | 1 |
| Vrachatis, D | 1 |
| Iakovou, I | 1 |
| Papaioannou, TG | 2 |
| Tousoulis, D | 2 |
| Leucker, TM | 1 |
| Vavuranakis, M | 2 |
| Seoudy, H | 1 |
| Thomann, M | 1 |
| Frank, J | 1 |
| Lutz, M | 1 |
| Puehler, T | 1 |
| Lutter, G | 1 |
| Müller, OJ | 1 |
| Frey, N | 1 |
| Saad, M | 1 |
| Frank, D | 1 |
| Lee, SI | 1 |
| Lee, KS | 1 |
| Kim, JB | 1 |
| Choo, SJ | 1 |
| Chung, CH | 1 |
| Lee, JW | 1 |
| Jung, SH | 1 |
| Yanagisawa, R | 1 |
| Jinzaki, M | 1 |
| Holy, EW | 1 |
| Kebernik, J | 1 |
| Allali, A | 1 |
| El-Mawardy, M | 1 |
| Richardt, G | 1 |
| Abdel-Wahab, M | 1 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Nardin, M | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Bundrick, JB | 1 |
| Litin, SC | 1 |
| Jimenez Diaz, VA | 1 |
| Cruz Gonzalez, I | 1 |
| Baz Alonso, JA | 1 |
| Molina Navarro, E | 1 |
| Juan Salvadores, P | 1 |
| Paredes Galan, E | 1 |
| De Miguel Castro, A | 1 |
| Bastos Fernandez, G | 1 |
| Ortiz Saez, A | 1 |
| Fernandez Barbeira, S | 1 |
| Raposeiras Roubin, S | 1 |
| Ocampo Miguez, J | 1 |
| Serra Peñaranda, A | 1 |
| Valdes Chavarri, M | 1 |
| Cequier Fillat, A | 1 |
| Calvo Iglesias, F | 1 |
| Iñiguez Romo, A | 1 |
| Guedeney, P | 1 |
| Mehran, R | 2 |
| Collet, JP | 2 |
| Claessen, BE | 1 |
| Ten Berg, J | 1 |
| Dangas, GD | 2 |
| Chung, EYM | 1 |
| Tiku, A | 1 |
| Seeho, S | 1 |
| Mather, A | 1 |
| Lynch, DR | 1 |
| Dantzler, D | 1 |
| Robbins, M | 1 |
| Zhao, D | 1 |
| Delaney, JA | 1 |
| Lehmann, N | 1 |
| Jöckel, KH | 1 |
| Elmariah, S | 1 |
| Psaty, BM | 1 |
| Mahabadi, AA | 1 |
| Budoff, M | 1 |
| Kronmal, RA | 1 |
| Nasir, K | 1 |
| O'Brien, KD | 1 |
| Möhlenkamp, S | 1 |
| Moebus, S | 1 |
| Dragano, N | 1 |
| Winterstein, AG | 1 |
| Erbel, R | 2 |
| Kälsch, H | 1 |
| Efthymiou, CA | 1 |
| Mills, RJ | 1 |
| O'Regan, DJ | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Hwang, HY | 1 |
| Ahn, H | 1 |
| Généreux, P | 1 |
| Cohen, DJ | 1 |
| Mack, M | 1 |
| Yadav, M | 1 |
| Xu, K | 1 |
| Parvataneni, R | 1 |
| Hahn, R | 1 |
| Kodali, SK | 1 |
| Webb, JG | 1 |
| Leon, MB | 1 |
| Kazi, DS | 1 |
| Gandhi, S | 1 |
| Schwalm, JD | 1 |
| Velianou, JL | 1 |
| Natarajan, MK | 1 |
| Farkouh, ME | 1 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Kikkert, WJ | 1 |
| Wiegerinck, EM | 1 |
| Ussia, GP | 2 |
| Sharma, S | 1 |
| Baan, J | 2 |
| Eltchaninoff, H | 1 |
| Rubino, P | 1 |
| Tamburino, C | 2 |
| Poliacikova, P | 1 |
| Blanchard, D | 1 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Iung, B | 1 |
| Orvin, K | 1 |
| Eisen, A | 1 |
| Perl, L | 1 |
| Zemer-Wassercug, N | 1 |
| Codner, P | 1 |
| Assali, A | 1 |
| Vaknin-Assa, H | 1 |
| Lev, EI | 1 |
| Kornowski, R | 1 |
| Magkoutis, NA | 1 |
| Fradi, S | 1 |
| Azmoun, A | 1 |
| Ramadan, R | 1 |
| Ben Ouanes, S | 1 |
| Vrachatis, DA | 1 |
| Ghostine, S | 1 |
| Bennaghmouch, N | 1 |
| Hassell, M | 1 |
| van Kuijk, JP | 1 |
| Agostoni, P | 1 |
| van 't Hof, A | 1 |
| Kievit, PC | 1 |
| Veenstra, L | 1 |
| van der Harst, P | 1 |
| van den Heuvel, AF | 1 |
| den Heijer, P | 1 |
| Kelder, JC | 1 |
| Deneer, VH | 1 |
| van der Kley, F | 1 |
| Onorati, F | 1 |
| Maisano, F | 1 |
| Latib, A | 1 |
| Huber, K | 1 |
| Stella, PR | 1 |
| Czerwińska-Jelonkiewicz, K | 1 |
| Zembala, M | 1 |
| Dąbrowski, M | 1 |
| Witkowski, A | 1 |
| Ochała, A | 1 |
| Kochman, J | 1 |
| Dudek, D | 1 |
| Kübler, P | 1 |
| Jagielak, D | 1 |
| Stępińska, J | 1 |
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Ichibori, Y | 1 |
| Mizote, I | 1 |
| Maeda, K | 1 |
| Onishi, T | 1 |
| Ohtani, T | 1 |
| Yamaguchi, O | 1 |
| Torikai, K | 1 |
| Kuratani, T | 1 |
| Sawa, Y | 1 |
| Nakatani, S | 1 |
| Sakata, Y | 1 |
| Giannini, C | 1 |
| De Carlo, M | 1 |
| Guarracino, F | 1 |
| Donne, MG | 1 |
| Benedetti, G | 1 |
| Verunelli, F | 1 |
| Petronio, AS | 1 |
| Yanagisawa, S | 1 |
| Suzuki, N | 1 |
| Tanaka, T | 1 |
| Nagler, M | 1 |
| Haslauer, M | 1 |
| Wuillemin, WA | 1 |
| Scarabelli, M | 1 |
| Mulè, M | 1 |
| Sarkar, K | 1 |
| Cammalleri, V | 1 |
| Immè, S | 1 |
| Aruta, P | 1 |
| Pistritto, AM | 1 |
| Gulino, S | 1 |
| Deste, W | 1 |
| Capodanno, D | 1 |
| Al-Rashid, F | 1 |
| Konorza, TF | 1 |
| Plicht, B | 1 |
| Wendt, D | 1 |
| Thielmann, M | 1 |
| Jakob, H | 1 |
| Kahlert, P | 1 |
| Al-Atassi, T | 1 |
| Lam, K | 1 |
| Forgie, M | 1 |
| Boodhwani, M | 1 |
| Rubens, F | 1 |
| Hendry, P | 1 |
| Masters, R | 1 |
| Goldstein, W | 1 |
| Bedard, P | 1 |
| Mesana, T | 1 |
| Ruel, M | 1 |
| Chirkov, YY | 1 |
| Holmes, AS | 1 |
| Willoughby, SR | 1 |
| Stewart, S | 1 |
| Horowitz, JD | 1 |
| Aoyagi, S | 1 |
| Arinaga, K | 1 |
| Fukunaga, S | 1 |
| Tayama, E | 1 |
| Kosuga, T | 1 |
| Akashi, H | 1 |
| Brinster, DR | 1 |
| Byrne, M | 1 |
| Rogers, CD | 1 |
| Baim, DS | 1 |
| Simon, DI | 1 |
| Couper, GS | 1 |
| Cohn, LH | 1 |
| Bugnicourt, JM | 1 |
| Bonnaire, B | 1 |
| Lepage, L | 1 |
| Garcia, PY | 1 |
| Lefranc, M | 1 |
| Godefroy, O | 1 |
| Brott, WH | 1 |
| Zajtchuk, R | 1 |
| Bowen, TE | 1 |
| Davia, J | 1 |
| Green, DC | 1 |
| Yankah, AC | 1 |
| Alexi-Meskhishvili, V | 1 |
| Weng, Y | 1 |
| Berger, F | 1 |
| Lange, P | 1 |
| Hetzer, R | 1 |
| Boon, A | 1 |
| Lodder, J | 1 |
| Cheriex, E | 1 |
| Kessels, F | 1 |
| Szczeklik, A | 1 |
| Musial, J | 1 |
| Pulka, G | 1 |
| Dudley, N | 1 |
| Aris, A | 1 |
| Pisciotta, AV | 1 |
| Hussey, CV | 1 |
| Gale, H | 1 |
| Lepley, D | 1 |
| Steele, P | 1 |
| Weily, H | 1 |
| Davies, H | 1 |
| Ppppas, G | 1 |
| Genton, E | 1 |
| Koike, T | 1 |
| Minakawa, T | 1 |
| Abe, H | 1 |
| Takeuchi, S | 1 |
| Sasaki, O | 1 |
| Nishimaki, K | 1 |
| Tanaka, R | 1 |
| Boldt, J | 1 |
| Knothe, C | 1 |
| Zickmann, B | 1 |
| Herold, C | 1 |
| Dapper, F | 1 |
| Hempelmann, G | 1 |
| Werler, MM | 1 |
| Mitchell, AA | 1 |
| Shapiro, S | 1 |
| Tsang, V | 1 |
| Jeremy, JY | 1 |
| Mikhailidis, DP | 1 |
| Walesby, RK | 1 |
| Wright, JC | 1 |
| Dandona, P | 1 |
| Mackay, A | 1 |
| de Bono, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement[NCT03557242] | 124 participants (Actual) | Interventional | 2018-07-05 | Active, not recruiting | |||
| Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial[NCT05283356] | Phase 4 | 1,206 participants (Anticipated) | Interventional | 2022-01-21 | Recruiting | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066] | Phase 4 | 65 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve[NCT00530894] | 1,057 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation[NCT02247128] | Phase 4 | 1,016 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause or repeat hospitalization after intervention. (NCT00530894)
Timeframe: duration of study
| Intervention | participants (Number) |
|---|---|
| Inoperable: TAVR | 76 |
| Inoperable: Medical Therapy | 126 |
Death from any cause. (NCT00530894)
Timeframe: 1 Year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 84 |
| High Risk: SAVR | 89 |
| Inoperable: TAVR | 55 |
| Inoperable: Medical Therapy | 89 |
NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. (NCT00530894)
Timeframe: Baseline to 1 year
| Intervention | Units on scale (Least Squares Mean) |
|---|---|
| High Risk: TAVR | 2.50 |
| High Risk: SAVR | 2.60 |
| Inoperable: TAVR | 2.88 |
| Inoperable: Medical Therapy | 3.92 |
Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure (NCT00530894)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 93 |
| High Risk: SAVR | 97 |
| Inoperable: TAVR | 61 |
| Inoperable: Medical Therapy | 93 |
Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization. (NCT00530894)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| High Risk: TAVR | 17.42 |
| High Risk: SAVR | 20.14 |
| Inoperable: TAVR | 25.24 |
| Inoperable: Medical Therapy | 17.04 |
"The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.~KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.~SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status." (NCT00530894)
Timeframe: Baseline and 1 Year
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| KCCQ Overall | SF-12 Physical | SF-12 Mental | |
| High Risk: SAVR | 71.1 | 36.9 | 52.9 |
| High Risk: TAVR | 70.0 | 36.3 | 52.0 |
| Inoperable: Medical Therapy | 46.98 | 29.68 | 46.59 |
| Inoperable: TAVR | 69.41 | 34.85 | 53.31 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
11 reviews available for aspirin and Aortic Valve Stenosis
| Article | Year |
|---|---|
Antithrombotic therapy after transcatheter aortic valve replacement: current perspective.
Topics: Aortic Valve; Aortic Valve Stenosis; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggr | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cause of Death; Clopidogrel; Dual Anti-Platelet Therapy; Endothelium | 2021 |
Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient-Level Meta-Analysis.
Topics: Aortic Valve Stenosis; Aspirin; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; | 2021 |
Dual Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve Replacement: Indirect Comparison and Meta-analysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination | 2018 |
Clinical pearls in general internal medicine.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Calcium; Cardiac Tamponade; Clavicle | 2018 |
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.
Topics: Anticoagulants; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Ther | 2019 |
Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Fibrinolytic Agents; Heart Val | 2013 |
Early postoperative thrombosis of an aortic bioprosthetic valve: should anticoagulation be patient specific?
Topics: Administration, Oral; Aged; Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Bioprosthe | 2013 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
13 trials available for aspirin and Aortic Valve Stenosis
| Article | Year |
|---|---|
Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Female; Hemorrhage; Humans; Male; Myoc | 2023 |
Aspirin Versus Warfarin after Transcatheter Aortic Valve Replacement in Low-Risk Patients: 2-Year Follow-Up.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Follow-Up Studies; Heart Valve Prosthe | 2023 |
Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial.
Topics: Aortic Valve Stenosis; Aspirin; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Transc | 2023 |
Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients.
Topics: Aortic Valve; Aortic Valve Stenosis; Aspirin; Heart Valve Prosthesis; Humans; Risk Factors; Transcat | 2021 |
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Anemia; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Comor | 2021 |
Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Fe | 2021 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; | 2019 |
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Echocardiography; Female; Foll | 2014 |
Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation.
Topics: Administration, Oral; Aortic Valve Stenosis; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2016 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Clinical Outcomes and Bioprosthetic Valve Function After Transcatheter Aortic Valve Implantation Under Dual Antiplatelet Therapy vs. Aspirin Alone.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Disease-Free S | 2017 |
Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Catheters; Clopidogrel; Drug Therap | 2011 |
Cerebral microembolization after bioprosthetic aortic valve replacement: comparison of warfarin plus aspirin versus aspirin only.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Collagen; Co | 2012 |
41 other studies available for aspirin and Aortic Valve Stenosis
| Article | Year |
|---|---|
No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry.
Topics: Aortic Valve; Aortic Valve Stenosis; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platele | 2023 |
Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Val | 2020 |
Single or Dual Antiplatelet Treatment after TAVI.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Transcatheter | 2021 |
Single or Dual Antiplatelet Treatment after TAVI.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Transcatheter | 2021 |
Single or Dual Antiplatelet Treatment after TAVI.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Transcatheter | 2021 |
Aspirin Versus Clopidogrel as Single Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry.
Topics: Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Platelet Agg | 2021 |
The impact of antiplatelet and antithrombotic regimen after TAVI: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY).
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Austria; Clopidogrel; Dual | 2021 |
Spontaneous Spinal Epidural Hematoma in an Adult Patient with Complex Congenital Heart Disease.
Topics: Adult; Anticoagulants; Aortic Valve Stenosis; Aspirin; Heart Defects, Congenital; Heart Septal Defec | 2021 |
Procedural outcomes in patients with dual versus single antiplatelet therapy prior to transcatheter aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Drug Therapy, Combination; Fe | 2021 |
Early Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement in Elderly Patients: A Single-Center Experience.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Chi-S | 2017 |
Spontaneous Regression of Possible Transcatheter Aortic Valve Thrombosis Without Additional Anticoagulant: Two-Year Follow-Up.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Drug Administration Schedule; Follo | 2017 |
Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis.
Topics: Administration, Oral; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; | 2017 |
Significant infrarenal aortic stenosis in pregnancy: a case report.
Topics: Adult; Aortic Valve Stenosis; Aspirin; Calcium; Calcium-Regulating Hormones and Agents; Cesarean Sec | 2019 |
Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aortic Valve Stenosis; Aspirin; Ca | 2013 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Routine aortic valve replacement for mild stenosis is not necessary during rheumatic mitral surgery.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Aspirin; Female; He | 2014 |
From innovation to implementation: optimizing long-term outcomes after TAVR.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Ticlopidine; Transcat | 2014 |
Antithrombotic therapy after transcatheter aortic valve implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Female; Heart Valve Prosthesis | 2015 |
Platelet reactivity in patients undergoing transcatheter aortic valve implantation.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2016 |
Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations.
Topics: Administration, Oral; Anticoagulants; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Com | 2016 |
Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry - POL-TAVI.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Female; Heart Valve P | 2017 |
Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Clopidogrel; Combined M | 2013 |
Poor tolerance of beta-blockers by elderly patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin Receptor Antagonists; Aortic Valve Steno | 2010 |
Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valve.
Topics: Anticoagulants; Aortic Valve Stenosis; Aspirin; Drug Therapy, Combination; Fondaparinux; Heart Valve | 2011 |
Transient increase in pressure gradients after termination of dual antiplatelet therapy in a patient after transfemoral aortic valve implantation.
Topics: Aged; Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Dyspnea; Echocardiograph | 2012 |
Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiovascula | 2002 |
Leaflet movement of the ATS valve in the aortic position: unique behavior observed in 19-mm valves.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Sten | 2006 |
Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease ("hybrid approach").
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Coronary Disease | 2006 |
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvasta | 2008 |
Dipyridamole-aspirin as thromboembolic prophylaxis in patients with aortic valve prosthesis. Prospective study with the Model 2320 Starr-Edwards prosthesis.
Topics: Adult; Aged; Aortic Valve; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Dipyridamole; Drug Therapy | 1981 |
Performance of aortic and pulmonary homografts in the right ventricular outflow tract in children.
Topics: Age Factors; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Cardiac Catheterization; Chil | 1995 |
Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis.
Topics: Age Factors; Aged; Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Cause o | 1996 |
Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma (AIA).
Topics: Aortic Valve Stenosis; Aspirin; Asthma; Autoimmune Diseases; Female; Humans; Middle Aged; Vasculitis | 1997 |
Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper.
Topics: Aged; Anticoagulants; Aortic Valve Stenosis; Aspirin; Atrial Fibrillation; Communication; Decision M | 2001 |
Open-heart surgery in von Willebrand's disease.
Topics: Aortic Valve Stenosis; Aspirin; Blood Coagulation; Blood Coagulation Tests; Blood Transfusion; Cardi | 1975 |
Platelet survival time following aortic valve replacement.
Topics: Adult; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Aspirin; Blood Platelets; Ce | 1975 |
PTA of supra-aortic arteries with temporary balloon occlusion to avoid distal embolism.
Topics: Adult; Angioplasty, Balloon; Aortic Valve Stenosis; Aspirin; Brain Diseases; Carotid Artery Thrombos | 1992 |
The effects of preoperative aspirin therapy on platelet function in cardiac surgery.
Topics: Adult; Aged; Aortic Valve Stenosis; Aspirin; Blood Coagulation Tests; Blood Loss, Surgical; Coronary | 1992 |
The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects.
Topics: Abnormalities, Drug-Induced; Aortic Coarctation; Aortic Valve Stenosis; Aspirin; Case-Control Studie | 1989 |
Release of prostacyclin from the human aorta.
Topics: Adult; Aged; Aorta; Aortic Valve Insufficiency; Aortic Valve Stenosis; Aspirin; Coronary Disease; Ep | 1988 |
Valvar aortic stenosis in adults: an update.
Topics: Adult; Anticoagulants; Aortic Valve Stenosis; Aspirin; Calcinosis; Dipyridamole; Echocardiography; E | 1986 |